December 12, 2024

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025
Go back

Innovators wanted. APPLY NOW!
WE SUPPORT YOUR INNOVATIVE INVENTION!

The work group of the BioRegions in Germany is the central network of regional initiatives promoting the economic use of modern biotechnologies in Germany. It annually awards the Innovation Prize of the BioRegions in Germany. This year, the work group again recognizes application-oriented ideas with strong implementation potential and showcases them at the German Biotech Days.

What is awarded?

  • The Innovation Prize honors innovative ideas that are patented or have been submitted for patenting.
  • We seek application-oriented ideas with strong implementation potential and high market opportunities.
  • Our aim is to support outstanding innovations that can significantly contribute to the economy and society.

Who can apply?

  • Scientists from universities and non-university institutions
  • Legal entities under public law, such as universities, universities of applied sciences, or patent exploitation agencies
  • Founders of companies that have not yet generated significant revenue and have not transferred substantial company shares to external investors

What do we offer?

  • Invitation for six finalists to the German Biotech Days on April 9 and 10, 2025, in Heidelberg
  • Presentation to an international audience, financiers, and the trade press
  • Three awards, each worth €2,000
  • An audience award worth €2,000

Apply now!

Application Deadline: February 14, 2025.

TO THE APPLICATION
Innopreis_2025_Flyer_EDownload

Our latest News

discover more
New software helps researchers decode the cellular architecture of lymphoma

New software helps researchers decode the cellular architecture of lymphoma

An open-source analysis framework developed by researchers at EMBL, HHU, and other institutions makes it easier to study how cells are organised within tumours, paving the way for new insights into cancer biology Summary How cancer develops and responds to treatment depends not only on the tumour cells themselves but also on the complex ecosystem […]

read more
EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing

EMBL spin-off Epitome Therapeutics launches to advance precision epigenome editing

The spin-off aims to develop a new generation of precision medicines using epigenome editing to precisely regulate gene expression without altering DNA A newly launched EMBL spin-off, Epitome Therapeutics, aims to translate pioneering research in epigenome editing into a new generation of precision medicines. Co-founded by EMBL Group Leader Jamie Hackett, the company builds on cutting-edge […]

read more
Complex Simulations: New Findings on Proton Transport in Water

Complex Simulations: New Findings on Proton Transport in Water

International research team simulates motions of a hydrated proton in full quantum detail Complex simulations – the most intricate of their kind to date – reveal how water governs the way protons move through it. They were carried out by an international research team led by scientists of Heidelberg University’s Institute for Physical Chemistry. Using […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp